ESPR Quote, Financials, Valuation and Earnings

Ardelyx has a net margin of -30.85% compared to Esperion Therapeutics's net margin of 4%. Esperion Therapeutics's return on equity of -- beat Ardelyx's return on equity of -24.57%.

Esperion Therapeutics has a consensus price target of $6.63, signalling upside risk potential of 342.08%. On the other hand Ardelyx has an analysts' consensus of $10.75 which suggests that it could grow by 118.05%. Given that Esperion Therapeutics has higher upside potential than Ardelyx, analysts believe Esperion Therapeutics is more attractive than Ardelyx.

Esperion Therapeutics has a beta of 1.042, which suggesting that the stock is 4.237% more volatile than S&P 500. In comparison Ardelyx has a beta of 0.873, suggesting its less volatile than the S&P 500 by 12.739%.

Esperion Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Ardelyx offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Esperion Therapeutics pays -- of its earnings as a dividend. Ardelyx pays out -- of its earnings as a dividend.

Esperion Therapeutics quarterly revenues are $69.1M, which are smaller than Ardelyx quarterly revenues of $116.1M. Esperion Therapeutics's net income of -$21.3M is lower than Ardelyx's net income of $4.6M. Notably, Esperion Therapeutics's price-to-earnings ratio is -- while Ardelyx's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Esperion Therapeutics is 0.87x versus 3.48x for Ardelyx. Usually stocks with elevated PS ratios are considered overvalued.

NovaBay Pharmaceuticals has a net margin of -30.85% compared to Esperion Therapeutics's net margin of -49.65%. Esperion Therapeutics's return on equity of -- beat NovaBay Pharmaceuticals's return on equity of -461.38%.

Esperion Therapeutics has a consensus price target of $6.63, signalling upside risk potential of 342.08%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of $0.85 which suggests that it could grow by 39.8%. Given that Esperion Therapeutics has higher upside potential than NovaBay Pharmaceuticals, analysts believe Esperion Therapeutics is more attractive than NovaBay Pharmaceuticals.

Esperion Therapeutics has a beta of 1.042, which suggesting that the stock is 4.237% more volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.726, suggesting its less volatile than the S&P 500 by 27.363%.

Esperion Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Esperion Therapeutics pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.

Esperion Therapeutics quarterly revenues are $69.1M, which are larger than NovaBay Pharmaceuticals quarterly revenues of $2.4M. Esperion Therapeutics's net income of -$21.3M is lower than NovaBay Pharmaceuticals's net income of -$1.2M. Notably, Esperion Therapeutics's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Esperion Therapeutics is 0.87x versus 0.06x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Palatin Technologies has a net margin of -30.85% compared to Esperion Therapeutics's net margin of -2357.27%. Esperion Therapeutics's return on equity of -- beat Palatin Technologies's return on equity of --.

Esperion Therapeutics has a consensus price target of $6.63, signalling upside risk potential of 342.08%. On the other hand Palatin Technologies has an analysts' consensus of $7.00 which suggests that it could grow by 957.24%. Given that Palatin Technologies has higher upside potential than Esperion Therapeutics, analysts believe Palatin Technologies is more attractive than Esperion Therapeutics.

Esperion Therapeutics has a beta of 1.042, which suggesting that the stock is 4.237% more volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.793, suggesting its less volatile than the S&P 500 by 20.66%.

Esperion Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Esperion Therapeutics pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.

Esperion Therapeutics quarterly revenues are $69.1M, which are larger than Palatin Technologies quarterly revenues of $350K. Esperion Therapeutics's net income of -$21.3M is lower than Palatin Technologies's net income of -$2.4M. Notably, Esperion Therapeutics's price-to-earnings ratio is -- while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Esperion Therapeutics is 0.87x versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.

Xeris Biopharma Holdings has a net margin of -30.85% compared to Esperion Therapeutics's net margin of -8.51%. Esperion Therapeutics's return on equity of -- beat Xeris Biopharma Holdings's return on equity of -1019.2%.

Esperion Therapeutics has a consensus price target of $6.63, signalling upside risk potential of 342.08%. On the other hand Xeris Biopharma Holdings has an analysts' consensus of $6.08 which suggests that it could grow by 12.01%. Given that Esperion Therapeutics has higher upside potential than Xeris Biopharma Holdings, analysts believe Esperion Therapeutics is more attractive than Xeris Biopharma Holdings.

Esperion Therapeutics has a beta of 1.042, which suggesting that the stock is 4.237% more volatile than S&P 500. In comparison Xeris Biopharma Holdings has a beta of 1.615, suggesting its more volatile than the S&P 500 by 61.462%.

Esperion Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Xeris Biopharma Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Esperion Therapeutics pays -- of its earnings as a dividend. Xeris Biopharma Holdings pays out -- of its earnings as a dividend.

Esperion Therapeutics quarterly revenues are $69.1M, which are larger than Xeris Biopharma Holdings quarterly revenues of $60.1M. Esperion Therapeutics's net income of -$21.3M is lower than Xeris Biopharma Holdings's net income of -$5.1M. Notably, Esperion Therapeutics's price-to-earnings ratio is -- while Xeris Biopharma Holdings's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Esperion Therapeutics is 0.87x versus 4.03x for Xeris Biopharma Holdings. Usually stocks with elevated PS ratios are considered overvalued.